RT Journal Article
SR Electronic
T1 SARS-CoV-2 viral dynamics in acute infections
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.10.21.20217042
DO 10.1101/2020.10.21.20217042
A1 Stephen M. Kissler
A1 Joseph R. Fauver
A1 Christina Mack
A1 Scott W. Olesen
A1 Caroline Tai
A1 Kristin Y. Shiue
A1 Chaney C. Kalinich
A1 Sarah Jednak
A1 Isabel M. Ott
A1 Chantal B.F. Vogels
A1 Jay Wohlgemuth
A1 James Weisberger
A1 John DiFiori
A1 Deverick J. Anderson
A1 Jimmie Mancell
A1 David D. Ho
A1 Nathan D. Grubaugh
A1 Yonatan H. Grad
YR 2020
UL http://medrxiv.org/content/early/2020/12/01/2020.10.21.20217042.abstract
AB Background SARS-CoV-2 infections are characterized by viral proliferation and clearance phases and can be followed by low-level viral RNA shedding. The dynamics of viral RNA concentration, particularly in the early stages of infection, can inform clinical measures and interventions such as test-based screening.Methods We used prospective longitudinal RT-qPCR testing to measure the viral RNA trajectories for 68 individuals during the resumption of the 2019-20 National Basketball Association season. For 46 individuals with acute infections, we inferred the peak viral concentration and the duration of the viral proliferation and clearance phases.Findings On average, viral RNA concentrations peaked 2.7 days (95% credible interval [1.2, 3.8]) after first detection at a cycle threshold value of 22.4 [20.6, 24.1]. The viral clearance phase lasted longer for symptomatic individuals (10.5 days [6.5, 14.0]) than for asymptomatic individuals (6.7 days [3.2, 9.2]). A second test within 2 days after an initial positive PCR substantially improves certainty about a patient’s infection phase. The effective sensitivity of a test intended to identify infectious individuals declines substantially with test turnaround time.Interpretation SARS-CoV-2 viral concentrations peak rapidly regardless of symptoms. Sequential tests can help reveal a patient’s progress through infection stages. Frequent rapid-turnaround testing is needed to effectively screen individuals before they become infectious.Funding NWO Rubicon 019.181EN.004 (CBFV); clinical research agreement with the NBA and NBPA (NDG); Huffman Family Donor Advised Fund (NDG); Fast Grant funding from the Emergent Ventures at the Mercatus Center; George Mason University (NDG); the Morris-Singer Fund for the Center for Communicable Disease Dynamics at the Harvard T.H. Chan School of Public Health (YHG).Evidence before this study SARS-CoV-2 viral dynamics affect clinical and public health measures, informing patient care, testing algorithms, contact tracing protocols, and clinical trial design. We searched Web of Science using the search terms “ALL = ((SARS-CoV-2 OR COVID-19) AND (viral OR RNA) AND (load OR concentration OR shedding) AND (dynamic* OR kinetic* OR trajector*))” which returned 83 references. Of these, 22 were not pertinent to within-host SARS-CoV-2 viral dynamics. The remaining 61 studies tracked SARS-CoV-2 viral trajectories in a variety of geographic locations and patient populations. Together, these studies report that viral titers normally peak at or before the onset of symptoms and that a long tail of intermittent positive tests can follow a period of acute infection. Plasma but not nasopharyngeal viral concentration is associated with increased disease severity. Most studies tracked hospitalized patients after the onset of symptoms. Two of the studies tracked pre-symptomatic and/or asymptomatic patients, but these were too sparsely sampled to clearly discern viral dynamics during the earliest stage of infection.Added value of this study We implemented prospective longitudinal real time quantitative reverse transcriptase polymerase chain reaction (RT-qPCR) testing for SARS-CoV-2 in a cohort of individuals during the resumption of the 2019-20 National Basketball Association season. This allowed us to explicitly measure viral titers during the full course of 46 acute infections. Consistent with other studies, we find that peak viral concentrations do not differ substantially between symptomatic and asymptomatic individuals but that symptomatic individuals take longer to clear the virus than asymptomatic individuals. For both symptomatic and asymptomatic individuals, viral titers normally peak within 3 days of the first positive test. This study is the first to describe the time course of viral concentrations during the earliest stage of infection when individuals are most likely to be infectious.Implications of all the available evidence Symptomatic and asymptomatic individuals follow similar SARS-CoV-2 viral trajectories. Due to the rapid progression from first possible detection to peak viral concentration, frequent rapid-turnaround testing is needed to screen individuals prior to them becoming infectious.Competing Interest StatementJW is an employee of Quest Diagnostics. JW is an employee of Bioreference Laboratories. NDG receives financial support from Tempus to develop SARS-CoV-2 diagnostic tests. SMK, SWO, and YHG have a consulting agreement with the NBA.Funding StatementThis study was funded by the NWO Rubicon 019.181EN.004 (CBFV), a clinical research agreement with the NBA and NBPA (NDG), the Huffman Family Donor Advised Fund (NDG), Fast Grant funding support from the Emergent Ventures at the Mercatus Center, George Mason University (NDG), and the Morris-Singer Fund for the Center for Communicable Disease Dynamics at the Harvard T.H. Chan School of Public Health (YHG).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:In accordance with the guidelines of the Yale Human Investigations Committee, this work with de-identified samples was approved for research not involving human subjects by the Yale Internal Review Board (HIC protocol # 2000028599). This project was designated exempt by the Harvard IRB (IRB20-1407).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesCode and data are available at https://github.com/gradlab/CtTrajectories https://github.com/gradlab/CtTrajectories